Immunogenicity of convalescent and vaccinated sera against clinical isolates of ancestral SARS-CoV-2, Beta, Delta, and Omicron variants

Simple item page

Simple item page

Full item details

dc.contributor.author
Banerjee, Arinjay
Lew, Jocelyne
Kroeker, Andrea
Baid, Kaushal
Aftanas, Patryk
Nirmalarajah, Kuganya
Maguire, Finlay
Kozak, Robert
McDonald, Ryan
Lang, Amanda
Gerdts, Volker
Straus, Sharon E.
Gilbert, Lois
Li, Angel Xinliu
Mozafarihashjin, Mohammad
Walmsley, Sharon
Gingras, Anne-Claude
Wrana, Jeffrey L.
Mazzulli, Tony
Colwill, Karen
McGeer, Allison J.
Mubareka, Samira
Falzarano, Darryl
dc.date.accessioned
2025-02-03T16:20:14Z
dc.date.available
2025-02-03T16:20:14Z
dc.date.issued
2022-06-10
dc.description.abstract - en
<p>Background: SARS-CoV-2 Omicron variant of concern (VOC) has evolved multiple mutations within the spike protein, raising concerns of increased antibody evasion. In this study, we assessed the neutralization potential of COVID-19 convalescent sera and sera from vaccinated individuals against ancestral SARS-CoV-2 and VOCs.</p> <p>Methods: The neutralizing activity of sera from 65 coronavirus disease (COVID-19) vaccine recipients and convalescent individuals against clinical isolates of ancestral SARS-CoV-2 and Beta, Delta, and Omicron VOCs was assessed using a micro-neutralization assay.</p> <p>Findings: Convalescent sera from unvaccinated individuals infected by the ancestral virus demonstrated reduced neutralization against Beta and Omicron VOCs. Sera from individuals that received three doses of the Pfizer or Moderna vaccines demonstrated reduced neutralization of the Omicron variant relative to ancestral SARS-CoV-2. Sera from individuals that were naturally infected with ancestral SARS-CoV-2 and subsequently received two doses of the Pfizer vaccine induced significantly higher neutralizing antibody levels against ancestral virus and all VOCs. Infection alone, either with ancestral SARS-CoV-2 or the Delta variant, was not sufficient to induce high neutralizing antibody titers against Omicron.</p> <p>Conclusions: In summary, we demonstrate that convalescent and vaccinated sera display varying levels of SARS-CoV-2 VOC neutralization. Data from this study will inform booster vaccination strategies against SARS-CoV-2 VOCs.</p>
dc.description.sponsorship
This research was funded by the Canadian Institutes of Health Research (CIHR). VIDO receives operational funding from the Government of Saskatchewan through Innovation Saskatchewan and the Ministry of Agriculture and from the Canada Foundation for Innovation through the Major Science Initiatives for its CL3 facility.
dc.identifier.doi
https://doi.org/10.1016/j.medj.2022.04.002
dc.identifier.issn
2666-6340
dc.identifier.pubmedID
35437520
dc.identifier.uri
https://open-science.canada.ca/handle/123456789/3389
dc.language.iso
en
dc.publisher - en
Elsevier Inc.
dc.rights - en
Creative Commons Attribution-NonCommercial-NoDerivatives 4.0 International (CC BY-NC-ND 4.0)
dc.rights - fr
Creative Commons Attribution - Pas d'utilisation commerciale - Pas de modification 4.0 International (CC BY-NC-ND 4.0)
dc.rights.uri - en
https://creativecommons.org/licenses/by-nc-nd/4.0/
dc.rights.uri - fr
https://creativecommons.org/licenses/by-nc-nd/4.0/deed.fr
dc.subject - en
Health
Coronavirus diseases
Immunization
dc.subject - fr
Santé
Maladie à coronavirus
Immunisation
dc.subject.en - en
Health
Coronavirus diseases
Immunization
dc.subject.fr - fr
Santé
Maladie à coronavirus
Immunisation
dc.title - en
Immunogenicity of convalescent and vaccinated sera against clinical isolates of ancestral SARS-CoV-2, Beta, Delta, and Omicron variants
dc.type - en
Article
dc.type - fr
Article
local.article.journaltitle - en
Med
local.article.journalvolume
3
local.pagination
422-432, e1-e3
local.peerreview - en
Yes
local.peerreview - fr
Oui
Download(s)

Original bundle

Now showing 1 - 1 of 1

Thumbnail image

Name: banerjee-immunogenicity-convalescent-vaccinated-sera-sars-cov-2-variants.pdf

Size: 2.49 MB

Format: PDF

Download file

Page details

Date modified: